1. Caring
Competitive medical insurance
options
Generous vacation allowances
Generous retirement program
Education reimbursement
Life, Disability, Long-Term Disability
and Travel insurance
Company-sponsored training
Flexible work schedules
Maternity/Paternity Leave
Recognizing Excellence Program
(RXP)
Length of Service Awards
Annual bonus plan
Launch parties, team building and
“Summer Sizzlers”
MyShireBenefits
include:
Global
We market our
products in
100+
countries
68 countries
Offices in
employees worldwide
22,000+
Agile research approach allows researchers to
propose a range of programs. Collaborative
partners include:
CollaborativeResponsible
Newsweek #1 Greenest Company in the world
2016 Award
Global 100 Most Sustainable Corporations in
the World, 2015
Partners with Direct Relief to offer rare disease
treatments around the world
Partners with AmeriCares, providing medicines
and other donations totaling more than $80
million, to people in more than 50 countries
Fondazione
Boston
Hospital
Children’s
Telethon
in Italy
Cincinnati
Children’s
Hospital
Pittsburgh
Children’s
Hospital
Therapeutic Leadership
Diverse products in six therapeutic areas
Hematology
$3,627m
All 2015 sales
• Leaders in personalized
treatments of hemophilia
and other blood disorders
Neuroscience
$2,200m
All 2015 sales
• 20+ years treating ADHD
• 5 products including
Adderall Xr
Oncology
$87m
All 2015 sales
• Oncaspar
Immunology
$2,516m
All 2015 sales
• 7 products
Hereditary
Angioedema &
Lysosomal
$1,501m
All 2015 sales
• Storage Disorders
• 6 products
Gastrointestinal &
Internal Medicine
$2,399m
All 2015 sales
• 6 products
Growing
Over 30 years of proven success.
Our Vision:
Double sales to $10 billion by 2020
Focused innovation on rare diseases with high
unmet medical need
Establishing leadership position and educating
physicians and parents about rare and specialist
conditions
Developing research, partnerships, capabilities,
and talent to expand our impact
40+ programs in pipeline
On track to file at least two INDs from internal
programs every year
Many significant clinical milestones anticipated in
the next 18 months
•
•
•
•
•
•
Innovative Pipeline
5 14 17 5 2
Phase 1 Phase 2 Phase 3 Registration Recent
approvals
1 2 3 R RA
Stage
Number of
programs
$648M
in 2000
$6.4B
in 2015
10x growth over last 15 years
Why Choose Shire?
Shire is a leading global biotech, serving patients with
rare diseases and other highly specialized conditions.